Effect of omeprazole on the pharmacokinetics and toxicities of irinotecan in cancer patients: A prospective cross-over drug–drug interaction study  by van der Bol, Jessica M. et al.
E U R O P E A N J O U R N A L O F C A N C E R 4 7 ( 2 0 1 1 ) 8 3 1 –8 3 8
. sc iencedi rec t . comava i lab le a t wwwjournal homepage: www.ejconl ine.comEffect of omeprazole on the pharmacokinetics and toxicities
of irinotecan in cancer patients: A prospective cross-over
drug–drug interaction study 5Jessica M. van der Bol *, Walter J. Loos, Floris A. de Jong, Esther van Meerten,
Inge R.H.M. Konings, Mei H. Lam, Peter de Bruijn, Erik A.C. Wiemer,
Jaap Verweij, Ron H.J. Mathijssen
Department of Medical Oncology, Erasmus MC – Daniel den Hoed Cancer Center, University Medical Center, Rotterdam, The NetherlandsA R T I C L E I N F O
Article history:
Received 23 November 2010
Accepted 26 November 2010
Available online 6 January 2011
Keywords:
Irinotecan
Omeprazole
Drug–drug interaction
Pharmacokinetics
Toxicities
Neutropenia
Diarrhoea
CYP3A
UGT1A0959-8049 2010 Elsevier Ltd.
doi:10.1016/j.ejca.2010.11.030
5 This work was presented at the Annual M
# 2502).
* Corresponding author: Address: Departme
Translational Pharmacology, Room AS-24, G
7041053.
E-mail address: jmvanderbol@gmail.com
Open access under A B S T R A C T
Background: Omeprazole is one of the most prescribed medications worldwide and within
the class of proton pump inhibitors, it is most frequently associated with drug interactions.
In vitro studies have shown that omeprazole can alter the function of metabolic enzymes
and transporters that are involved in the metabolism of irinotecan, such as uridine diphos-
phate glucuronosyltransferase subfamily 1A1 (UGT1A1), cytochrome P-450 enzymes
subfamily 3A (CYP3A) and ATP-binding cassette drug-transporter G2 (ABCG2). In this
open-label cross-over study we investigated the effects of omeprazole on the pharmacoki-
netics and toxicities of irinotecan.
Methods: Fourteen patients were treated with single agent irinotecan (600 mg i.v., 90 min)
followed 3 weeks later by a second cycle with concurrent use of omeprazole 40 mg once
daily, which was started 2 weeks prior to the second cycle. Plasma samples were
obtained up to 55 h after infusion and analysed for irinotecan and its metabolites
7-ethyl-10-hydroxycampothecin (SN-38), SN-38-glucuronide (SN-38G), 7-ethyl-10-[4-(1-pip-
eridino)-1-amino]-carbonyloxycamptothecin (NPC) and 7-ethyl-10-[4-N-(5-aminopentanoic
acid)-1-piperidino]-carbonyloxycamptothecin (APC) by high-performance liquid chroma-
tography (HPLC). Non-compartmental modelling was performed. Toxicities were monitored
during both cycles. Paired statistical tests were performed with SPSS.
Results: The exposure to irinotecan and its metabolites was not significantly different
between both cycles. Neither were there significant differences in the absolute nadir and per-
centage decrease of WBC and ANC, nor on the incidence and severity of neutropenia, febrile
neutropenia, diarrhoea, nausea and vomiting when irinotecan was combined with omepra-
zole.
Conclusion: Omeprazole 40 mg did not alter the pharmacokinetics and toxicities of irinotecan.
This widely used drug can, therefore, be safely administered during a 3-weekly single agent
irinotecan schedule.
 2010 Elsevier Ltd. Open access under the Elsevier OA license.eeting of the American Society of Clinical Oncology 2009 in Orlando, FL, May 2009 (abstract
nt of Medical Oncology, Erasmus MC – Daniel den Hoed Cancer Center, Laboratory of
roene Hilledijk 301, 3075 EA Rotterdam, The Netherlands. Tel.: +31 10 7041937; fax: +31 10
(J.M. van der Bol).
the Elsevier OA license.
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especially in oncology, as a result of the narrow therapeutic
window of chemotherapeutic agents. Small changes in the
pharmacokinetics or pharmacodynamics of chemotherapy
caused by another drug can result in significant changes in
its toxicity or efficacy. Because cancer patients often experi-
ence disease- and age-related organ failure, they frequently
use several other drugs, which put them at risk for drug–drug
interactions.1
Proton pump inhibitors (PPIs) act as potent blockers of the
gastric acid pump without major side effects.2 They belong
to one of the most frequently prescribed medications in
the United States (http://www.imshealth.com/deployedfiles/CYP3A4/5
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Fig. 1 – Metabolism of irinotecan. The pro-drug irinotecan is
metabolised into its active metabolite SN-38 by carboxy-
lesterases type 1 and 2. The affinity for this reaction is low
since only a fraction of irinotecan is directly converted into
SN-38. Competing with the formation of SN-38 is the
oxidation of irinotecan into the inactive metabolites APC
and NPC by CYP3A4 and CYP3A5, which both (partially) can
be converted further into SN-38. To facilitate excretion, SN-
38 is glucuronidated into its inactive metabolite SN-38-
glucuronide (SN-38G) by several UGT1A isoforms; UGT1A1
being the most important. In the intestines, SN-38G can be
de-glucuronidated into SN-38 by b-glucuronidase-producing
bacteria. Several drug transporters are involved in the
elimination of irinotecan and its metabolites. Abbreviations
ABCB1, ATP-binding cassette drug-transporter B1, also
known as P-glycoprotein; ABCC2, ATP-binding cassette
drug-transporter C2, also known as canalicular multispec-
ific organic anion transporter (C-MOAT); ABCG2, ATP-bind-
ing cassette drug-transporter G2, also known as Breast
Cancer Resistance Protein (BCRP); APC, 7-ethyl-10-[4-N-
(5-aminopentanoic acid)-1-piperidino]-carbonyloxycampto-
thecin, inactive metabolite of irinotecan; CES, carboxylest-
erase; CYP3A; cytochrome P-450 enzymes subfamily 3A;
NPC, 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxy-
camptothecin, inactive metabolite of irinotecan; SN-38,
7-ethyl-10-hydroxycampothecin, active metabolite of irino-
tecan; SN-38G, SN-38-glucuronide, inactive metabolite of
SN-38; UGT1A, uridine diphosphate glucuronosyltransfer-
ase subfamily 1A.,
:imshealth/Global/Content/StaticFile/Top_Line_Data/Top%20
Therapy%20Classes%20by%20U.S.Sales.pdf).
Omeprazole was the first registered proton pump inhibitor
and is one of the most prescribed drugs worldwide (http://
cnnmoney.eu/2009/08/05/news/companies /top_generic_drugs.
fortune/index.htm and www.rxlist.com). Although widely
used, being approved as over-the-counter product in several
countries, and mostly designated as harmless, omeprazole
is actually known to be involved in several drug–drug
interactions,3 which could potentially be dangerous when
combined with drugs with a narrow therapeutic window,
such as chemotherapeutic agents.
Several drug–drug interaction studies with omeprazole
have been performed, mainly focusing on interactions on
the level of hepatic cytochrome P450 (CYP) enzymes and alter-
ation of the absorption of (oral) drugs via changes in gastric
pH. Clinically, the most important drug–drug interaction of
omeprazole is a 27–54% reduction in clearance of diazepam
due to competitive inhibition of CYP2C19.4,5 Next to this effect
there are in vivo and in vitro results pointing to induction of
UDP-glucuronosyltransferases,6–8 induction9,10 and inhibition
of cytochrome P-450 enzymes subfamily 3A (CYP3A),11,12 and
inhibition of the ATP-binding cassette drug-transporter B1
(ABCB1)11,12 and ATP-binding cassette drug-transporter G2
(ABCG2).13,14 These metabolising enzymes and drug trans-
porters play an important role in the disposition of the topo-
isomerase-I inhibitor irinotecan (Campto, Pfizer), which is
registered for the treatment of metastatic and/or inoperable
colorectal cancer (Fig. 1).
In vitro research of the combination of irinotecan and ome-
prazole showed an 85% reduction of 7-ethyl-10-[4-(1-piperidi-
no)-1-amino]-carbonyloxycamptothecin (NPC) formation, one
of the metabolites of irinotecan, which could potentially lead
to increased levels of the active metabolite 7-ethyl-10-
hydroxycampothecin (SN-38) and consequently more severe
toxicity.15 We performed comparable in vitro experiments
and the results led us to initiate a clinical study to investigate
the effect of omeprazole on the pharmacokinetics of irinotec-
an and toxicities in cancer patients.
2. Materials and methods
2.1. In vitro studies
In vitro experiments were performed to study the effect of
omeprazole on the metabolism of irinotecan. Pooled human
liver microsomes (Becton Dickinson Gentest) were incubated
for 30 min with irinotecan (10 lM) in the presence or absence
of omeprazole (25 lM) or fluconazole (25 lM; CYP3A inhibitor)
based on an earlier described method.16 The experiments
were performed on four separate occasions. In each experi-
ment, microsomes (1 mg protein/mL) were incubated in tripli-
cate. In another experiment, microsomes (0.8 mg/mL) were
co-incubated for 30 min with SN-38 (5 lM) and omeprazole
(25 lM) and ketoconazol (25 lM; uridine diphosphate glucu-
ronosyltransferase subfamily 1A [UGT1A] inhibitor) based on
methods described.17 Experiments were terminated by the
addition of perchloric acid/methanol. Irinotecan and metabo-
lite concentrations were analysed based on validated as-
says.18,19 HCT116 (colorectal carcinoma) and Caco2
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fered RPMI 1640 medium supplemented with Glutamax, 10%
foetal bovine serum (Gibco), 100 U/mL penicillin and 100 lg/
mL streptomycin at 37 C in a humidified atmosphere contain-
ing 5% CO2. Cells were cultured for 24 h in the presence of
25 lM omeprazole or 0.1% (v/v) DMSO as solute control. After
24 h, total RNAwas extracted using RNA-Bee (Tel-TEST Temco,
Inc.). RelativeUGT1A1 expression levels were measured by real
time RT-PCR using Taqman Universal Master mix and Assay-
On-Demand products from Applied Biosystems (UGT1A1
assay ID: Hs02511055-s1). The human glyceraldehyde-3-
phosphate dehydrogenase (GAPDH assay ID: 4310884E; VIC/
TAMRA) was used for normalisation. Reactions were run on
an ABI PRISM 7900 sequence detector system (Applied Biosys-
tems) using the following cycling conditions: 50 C for 2 min,
95 C for 10 min followed by 40 cycles of 95 C for 15 s, and
60 C for 1 min.
2.2. Patients
Nineteen patients were included in this open-label cross-over
interaction study. Inclusion criteria were: (1) histological or
cytological confirmed diagnosis of any form of (irresectable
and/or metastatic) cancer, which was thought to be sensitive
to irinotecan-treatment; (2) ageP 18 years; (3) WHO perfor-
mance score 6 1; and (4) adequate haematological, renal
and hepatic function. Starting 2 weeks before irinotecan
administration, patients were not allowed to use grapefruit,
star fruit, dietary supplements, St. John’s wort, herbal tea
and herbals or any other known inhibitor and/or inducer of
CYP3A and ABCB1. In addition, the use of proton pump inhib-
itors was prohibited. Specific exclusion criteria were: (1) any
form of anti-cancer treatment within 4 weeks of start of irino-
tecan administration; (2) unresolved bowel obstruction or
chronic colic disease; and (3) any form of illness that would
prohibit the process of understanding and giving of informed
consent. All patients gave written informed consent and the
local institutional review board approved the clinical protocol,
which was written in accordance with the declaration of
Helsinki.
2.3. Treatment
All patients received their first cycle of irinotecan (Campto,
Pfizer) without and their second cycle with concomitant
omeprazole (LosecMUPS, AstraZeneca). Fourteen days be-
fore the start of the second cycle, patients started with ome-
prazole 40 mg once daily until the third day after the second
administration. Irinotecan was administered intravenously
over 90 min at a flat-fixed dose of 600 mg during both cy-
cles.20 All patients received a standard anti-emetic regimen
of intravenous granisetron (1 mg) and dexamethason
(10 mg) 30 min before the administration of irinotecan and
atropine (0.25 mg, subcutaneously) prior to irinotecan infu-
sion, to prevent an acute cholinergic syndrome. For the
treatment of irinotecan-induced diarrhoea, patients received
treatment with loperamide and, when necessary, antibiotics.
A dose-reduction of 25% was performed at the discretion of
the physician when necessary. Patients were asked to record
side-effects, the intake of any other drugs during both treat-ment cycles and the time of intake of omeprazole in a spe-
cific diary.2.4. Pharmacokinetic analyses of irinotecan
Pharmacokinetic analyses of irinotecan and its main metabo-
lites SN-38, SN-38G, APC and NPC were performed during
both treatment cycles. Blood samples (5 mL; lithium-hepar-
ine) were collected prior to infusion, 30 min after the start
of infusion, at the end of infusion, as well as 10, 20 and
30 min, and 1, 1.5, 2, 3, 4, 5, 6, 22.5, 30, 46.5 and 53.5 h post-
infusion. Samples were centrifuged for 10 min at 2860g
(4 C) and plasma was stored at –80 C until analysis by vali-
dated reversed-phase high-performance liquid chromatogra-
phy assays with fluorescence detection, as described
elsewhere.18,19,21 Pharmacokinetic parameters of irinotecan
and its metabolites were calculated using weighted non-com-
partmental analyses with WinNonLin 5.2 (Pharsight Corp.,
Mountain View, CA).
2.5. Toxicities
During both cycles, patients were seen weekly at the outpatient
clinic for physical examination, toxicity screening and labora-
tory tests. Leucopenia, neutropenia, diarrhoea, nausea and
vomiting were graded using the Common Terminology Criteria
for Adverse Events (CTC) version 3.0 (http://ctep.cancer.gov/
protocolDevelopment /electronic_applications/docs/ctcaev3.
pdf), and were also classified into severe (grade 3–4) and not
severe (grade 0–2). In addition, leucopenia and neutropenia
were evaluated as absolute nadir and as percentage decrease
at nadir from baseline which was calculated as percentage
decrease = [baseline value – nadir value]/baseline value ·
100%. Toxicity analyses were only performed in the group of
patients who received two full dose cycles of irinotecan
(600 mg; N = 12).2.6. Genotyping
In all patients, UGT1A1-genotype analyses were performed for
the UGT1A1*28 ((TA)6! (TA)7) and UGT1A1*93 (–3156G>A)
polymorphisms as described.22 In addition, patients were
screened for being an ultra-rapid metabolizer of CYP2C19
(CYP2C19*17),23 which may result in a sub-therapeutic expo-
sure to omeprazole.23,242.7. Statistics
The primary objective of this study was to investigate the
influence of omeprazole on the plasma pharmacokinetics of
irinotecan and its metabolites in cancer patients. To detect a
25% difference in SN-38 AUC between the cycles with and
without concomitant omeprazole with a two-sided signifi-
cance level of 5% and a power (1-b) of 90%, a sample size of
at least 14 patients was required. For the sample size calcula-
tion, data were used from patients who received two subse-
quent cycles of irinotecan at a flat-fixed dose of 600 mg.22
Dose-reduced patients were excluded from this analysis. The
secondary objective was to compare side effects, especially
Table 1 – Patient characteristics.a
Characteristics N % Median Range
834 E U R O P E A N J O U R N A L O F C A N C E R 4 7 ( 2 0 1 1 ) 8 3 1 –8 3 8leucopenia and neutropenia, and late-onset diarrhoea, in the
presence and absence of omeprazole.
Data are presented as mean values with 95% confidence
intervals unless stated otherwise. To compare pharmacologi-
cal parameters and nadir and percentage decrease of neutro-
phils and leucocytes between the cycle with and without
omeprazole, paired t-tests were used. For the comparison of
the CTC-graded toxicities between both cycles, Mc Nemar’s
test was used. Statistical tests were calculated two-sided
and P-values of less than 0.05 were regarded as statistically
significant. All statistical calculations were performed with
SPSS version 15.0 (SPSS Inc., Chicago, IL).
3. Results
3.1. In vitro experiments
As shown in Fig. 2, co-incubation of human liver microsomes
with irinotecan and omeprazole resulted in an 80% inhibition
on NPC formation and a 75% inhibition on APC formation,
which was comparable with results with the CYP3A inhibitor
fluconazole (78% and 74% inhibition, respectively). Although
in vitro no effect of omeprazole was seen on the formation
of SN-38, the inhibition of both NPC and APC formation could
potentially lead to higher SN-38 levels in vivo.NPC APC SN38
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Fig. 2 – Omeprazole affects the metabolism of irinotecan
in vitro. Effect of omeprazole (striped bars) and CYP3A
inhibitor fluconazole (open bars) on the formation of NPC,
APC and SN-38 during incubation of human liver micro-
somes with irinotecan and effect of omeprazole (striped
bars) and UGT1A1 inhibitor ketoconazole (open bars) on the
formation of SN-38G during incubation with SN-38. The
black bars represent the formation of metabolites in the
absence of a potential inhibitor. Depicted are the mean
values of the formed metabolite + SD. Abbreviations: APC 7-
ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino]-car-
bonyloxycamptothecin, inactive metabolite of irinotecan;
CYP3A; cytochrome P-450 enzymes subfamily 3A; NPC, 7-
ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycampto-
thecin, inactive metabolite of irinotecan; SN-38, 7-ethyl-10-
hydroxycampothecin, active metabolite of irinotecan; SN-
38G, SN-38-glucuronide, inactive metabolite of SN-38;
UGT1A1, uridine diphosphate glucuronosyltransferase
subfamily 1A1.Also shown in Fig. 2, co-incubation of human liver micro-
somes with SN-38 and omeprazole did not result in reduced
formation of SN-38G, whereas the formation of SN-38G was
reduced with 57% when SN-38 was co-incubated with the
UGT1A1 inhibitor ketoconazole.
A 24-h exposure of the colorectal carcinoma cell lines
HCT116 and Caco2 to 25 lM omeprazole resulted in a two-fold
upregulation of UGT1A1 mRNA levels as determined by quan-
titative RT-PCR.
3.2. Patients
Nineteen patients were included in the clinical study. Two pa-
tients did not start treatment after registration; one due to the
diagnosis of a second malignancy, the other due to progres-
sive liver failure. One patient did not receive a second admin-
istration of irinotecan because of severe toxicity during the
first cycle (grade 4 diarrhoea and haematological toxicity).
One patient was not evaluable for pharmacokinetics due
to ascites with possible third space pharmacokinetics.Age (years) 65 26–74
BSA (m2) 1.87 1.59–2.38
Sex
Male 9 64%
Female 5 36%
Tumour type
Colorectal 4 29%
Pancreatic 4 29%
(A)CUP 2 14%
Miscellaneousb 4 29%
Smoking status
Smoker 1 7%
Non-smoker 13 93%
UGT1A1*28 genotype
TA6/TA6 (wildtype) 7 50%
TA6/TA7 7 50%
TA7/TA7 0 0%
UGT1A1*93 genotype
GG (wildtype) 9 64%
GA 5 36%
AA 0 0%
CYP2C19*17 genotype
CC (wildtype) 5 36%
CT 7 50%
TT 2 14%
Abbreviations: (A)CUP, (adeno)carcinoma of unknown primary; BSA,
body surface area; UGT1A1*28, polymorphism for an additional
(seventh) repeat in the TATA box of the promotor region of UGT1A1
leading to reduced UGT1A1 formation; UGT1A1*93, polymorphism
in the UGT1A1 gene, also known as –3156G>A, resulting in less
functional UGT1A1; CYP2C19*17, polymorphism in CYP2C19 gene
(–806C>T and –3402C>T), resulting in more functional CYP2C19
(ultra rapid metabolizer).
a N = 14, patients evaluable for two treatment cycles.
b Including primitive neuro-ectodermal tumour (1), cholangiocar-
cinoma (1), jejunal carcinoma (1) and breast cancer (1).
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pharmacokinetic sampling. Of the 14 evaluable patients for
pharmacokinetics, two patients were not evaluable for toxic-
ity analysis due to 25% dose reduction during their second cy-
cle because of severe toxicity (grade 4 haematological toxicity
plus grade 3 gastro-intestinal toxicities and grade 3 hepato-
logical toxicity, respectively). The pharmacokinetics of these
dose-reduced cycles was extrapolated to full-dose pharmaco-
kinetics, since the pharmacokinetics of irinotecan and its
metabolites are linear in this dose range.25 Patient demo-
graphics are stated in Table 1.
3.3. Irinotecan pharmacokinetics
As shown in Table 2, there was no significant difference in the
area under the curve (AUC) and maximum concentration
(Cmax) of irinotecan (P > 0.24), SN-38 (P > 0.63), SN-38G
(P > 0.07), APC (P > 0.07) and NPC (P > 0.13) between the cycles
with and without omeprazole. Similar results were obtained
when the two ultra-rapid metabolizers of CYP2C19
(CYP2C19*17/*17) were left out of analysis (P > 0.06). Fig. 3
shows the time versus plasma-concentration curves of irino-
tecan and its metabolites as well as the intra-individual AUCs
with and without concomitant omeprazole.
3.4. Toxicities
No statistical differences were seen in the absolute nadir and
percentage decrease of leucocytes and neutrophils after irino-
tecan treatment with or without omeprazole (P > 0.34; Table 3).
In addition, no differences were seen in the incidence of se-
vere leucopenia and neutropenia (P = 1.0). Overall, the inci-Table 2 – Pharmacokinetics of irinotecan and its metabolites wi
Parametera Omeprazole (–)
Irinotecan
AUC0–55h (ngÆh/mL) 24,498 (16,186–32,811) 2
Cmax (ng/mL) 3700 (2998–4401) 3
SN-38
AUC0–55h (ngÆh/mL) 439 (346–533) 4
Cmax (ng/mL) 41.9 (29.9–53.9) 4
SN-38G
AUC0–55h (ngÆh/mL) 2913 (1874–3953) 3
Cmax (ng/mL) 209 (155–264) 2
APC
AUC0–55h (ngÆh/mL)
c 7471 (4944–9998) 6
Cmax (ng/mL)
c 587 (393–781) 4
NPC
AUC0–55h (ngÆh/mL) 189 (114–265) 1
Cmax (ng/mL) 19.9 (12.5–27.3) 1
Abbreviations: APC, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidi
AUC0–55h, area under the concentration–time curve from timepoint 0 to 55
1-amino]-carbonyloxycamptothecin, inactive metabolite of irinotecan; SN
SN-38G, SN-38-glucuronide, inactive metabolite of SN-38.
a Data presented as mean with 95% confidence interval in parentheses.
b Ratio of mean pharmacokinetic parameters of irinotecan with and wit
c N = 13, data on pharmacokinetics of APC missing in one patient.dence of severe (grade 3–4) gastro-intestinal toxicities was
low in our study. Only 2 patients suffered from grade 3 or 4
diarrhoea, nausea and vomiting.
4. Discussion
Here we investigated the possible drug–drug interaction be-
tween the proton pump inhibitor omeprazole and irinotecan.
No effect of the co-administration of omeprazole on the phar-
macokinetics and toxicities of irinotecan and its metabolites
was seen. Two patients in our study were characterised as
CYP2C19-ultra rapid metabolizers, which could have influ-
enced our results as they could have had suboptimal levels
of omeprazole. However, when these patients were excluded
from analysis, there still was no significant influence of ome-
prazole on the pharmacokinetics and toxicities of irinotecan
and its metabolites.
Since irinotecan has a complex disposition profile involv-
ing several drug metabolising enzymes and drug transporters,
drug–drug interactions can occur at several levels. In recent
years, several herbs and drugs were combined with irinotecan
to investigate the possibility of a drug interaction, potentially
explaining the occurrence of treatment failure or severe side
effects, such as neutropenia and late-onset diarrhoea. For
example, a reduced exposure to irinotecan and its potent
metabolite SN-38, was seen when irinotecan was combined
with the CYP3A inducer phenytoin.26,27 Concomitant smoking
also resulted in reduced plasma-concentrations of irinotecan
and SN-38.28 Reduced levels of SN-38 were seen when irino-
tecan was combined with valproic acid,29 and with St. John’s
wort.30 Higher levels of SN-38 were seen in combination with
lopinavir/ritonavir and the combined CYP3A and UGT1Athout (–) and with (+) concomitant use of omeprazole.
Omeprazole (+) Ratiob P
3,472 (16,195–30,748) 0.97 (0.92–1.02) 0.24
585 (2814–4355) 0.97 (0.90–1.04) 0.34
53 (354–551) 1.05 (0.92–1.19) 0.63
3.0 (31.7–54.3) 1.09 (0.87–1.31) 0.81
167 (1963–4371) 1.08 (0.96–1.19) 0.15
28 (165–291) 1.09 (1.00–1.19) 0.07
438 (5016–7859) 0.94 (0.80–1.07) 0.15
76 (378–575) 0.90 (0.77–1.04) 0.07
54 (119–189) 0.92 (0.75–1.09) 0.25
5.0 (12.5–17.5) 0.89 (0.72–1.05) 0.13
no]-carbonyloxycamptothecin, inactive metabolite of irinotecan;
h; Cmax, maximum concentration; NPC, 7-ethyl-10-[4-(1-piperidino)-
-38, 7-ethyl-10-hydroxycampothecin, active metabolite of irinotecan;
hout omeprazole [ratio = with omeprazole/without omeprazole].
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Fig. 3 – (A–J) Pharmacokinetics of irinotecan with and without concomitant omeprazole. (A–E) Mean (±95% confidence
interval) time versus plasma-concentration curves of irinotecan (A), SN-38 (B), SN-38G (C), APC (D) and NPC (E) in 14 cancer
patients after intravenous infusion of 600 mg irinotecan, with (closed circles) and without (open circles) concomitant use of
omeprazole 40 mg once daily. (F–J) Intra-individual (open circles) and mean (closed circle) area under the curve (AUC) of
irinotecan (F), SN-38 (G), SN-38G (H), APC (I, N = 13) and NPC (J) of 14 cancer patients treated with irinotecan 600 mg
intravenously with and without concomitant use of omeprazole 40 mg once daily. Abbreviations: APC, 7-ethyl-10-[4-N-(5-
aminopentanoic acid)-1-piperidino]-carbonyloxycamptothecin, inactive metabolite of irinotecan; NPC, 7-ethyl-10-[4-(1-
piperidino)-1-amino]-carbonyloxycamptothecin, inactive metabolite of irinotecan; SN-38, 7-ethyl-10-hydroxycampothecin,
active metabolite of irinotecan; SN-38G, SN-38-glucuronide, inactive metabolite of SN-38.
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Table 3 – Toxicities of irinotecan without (–) and with (+) concommitant use of omeprazole of patients who received two full-
dose treatments (N = 12)a.
Parameter Omeprazole (–) Omeprazole (+) P
Leucocytes
Nadir (·109) 2.79 (2.00–3.59) 3.01 (2.07–3.95) 0.46
Decrease (%)b 46.8 (31.3–62.4) 40.3 (17.6–63.0) 0.34
Severe leucopenia (grade 3–4)c 5 (42%) 4 (33%) 1.00d
Neutrophils
Nadir (·109) 1.47 (0.86–2.08) 1.43 (0.88–1.98) 0.87
Decrease (%)b 57.4 (41.8–73.1) 49.6 (25.3–74.0) 0.35
Severe neutropenia (grade 3–4)c 4 (33%) 5 (42%) 1.00d
a Two patients were excluded from this analysis because of dose reduction during the second cycle due to severe toxicities during the first cycle.
b Percentage decrease compared with baseline, [baseline value – nadir value]/baseline value · 100%.
c Number of patients with percentage in parentheses.
d Mc Nemar test.
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bined with tacrolimus.33 However, no effect was seen when
irinotecan was combined with medicinal cannabis.34
We detected a modest two-fold increase in UGT1A1 mRNA
levels when colorectal carcinoma cell lines were cultured with
omeprazole for 24 h. Similarly Donato et al. reported a six-
fold induction of UGT1A1 activity in HepG2 cells when they
were cultured in the presence of 50 lM omeprazole for
72 h.8 This can be explained by the agonistic effect of omepra-
zole on the Ah-receptor,35 which is known to be involved in
transcription of the UGT1A1 gene.36 However, in vivo omepra-
zole had no significant inducing effect on the glucuronidation
of SN-38, possibly because in vivo lower concentrations of the
drug are present.
Our results complement outcomes of other drug–drug
interaction studies with omeprazole and anti-cancer drugs.
For example, no effect of omeprazole was seen on the
pharmacokinetics of the CYP3A-substrates imatinib and
bortezomib.37,38 However, the exposure to dasatinib was
reduced in combination with omeprazole (http://www.
clinicalstudyresults.org /documents/company-study_1477_2.
pdf). The mechanism for this effect could be CYP3A4 induction
or reduced gastric acid secretion which influences the absorp-
tion of dasatinib. As irinotecan is administered intravenously,
the latter cannot play a role in a possible interaction. And, in
contrast with dasatinib, where only CYP3A4 is thought to play
an important role in its metabolism,39 irinotecan has multiple
enzymes that are involved in its disposition.
A limitation of our study might be the fixed-sequence de-
sign instead of a randomised design. We chose this design to
avoid a possible influence of the different sequences on the
pharmacokinetics of irinotecan and to avoid treatment delay
due to the 2-weeks induction-period for omeprazole.
Although the sample size was large enough to detect a possi-
ble difference in pharmacokinetics according to the power
analysis, this was a small study and the study was not pow-
ered to detect differences in toxicity outcome.
To conclude, our results indicate that omeprazole 40 mg
once daily can be safely combined with a single agent irino-
tecan schedule, administered once every 3 weeks. Since other
proton pump inhibitors have a different potential for drug–drug interactions,40 effect of other proton pump inhibitors
on the pharmacokinetics and toxicities of irinotecan should
be further investigated, before they might be safely combined
with irinotecan.
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